All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 324.80 points (-1.9%) at 16,666 as of Friday, Aug. 21, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 525 issues advancing vs. 2,498 declining with 133 unchanged.

The Drugs industry as a whole closed the day down 0.8% versus the S&P 500, which was down 1.7%. Top gainers within the Drugs industry included Skystar Bio-Pharmaceutical ( SKBI), up 3.6%, Cellectar Biosciences ( CLRB), up 1.7%, BioPharmX ( BPMX), up 5.9%, Echo Therapeutics ( ECTE), up 3.3% and Aptose Biosciences ( APTO), up 3.5%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Echo Therapeutics ( ECTE) is one of the companies that pushed the Drugs industry higher today. Echo Therapeutics was up $0.05 (3.3%) to $1.55 on heavy volume. Throughout the day, 93,852 shares of Echo Therapeutics exchanged hands as compared to its average daily volume of 43,300 shares. The stock ranged in a price between $1.46-$1.66 after having opened the day at $1.46 as compared to the previous trading day's close of $1.50.

Echo Therapeutics has a market cap of $16.9 million and is part of the health care sector. Shares are up 11.1% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, Cellectar Biosciences ( CLRB) was up $0.05 (1.7%) to $3.05 on light volume. Throughout the day, 5,504 shares of Cellectar Biosciences exchanged hands as compared to its average daily volume of 12,300 shares. The stock ranged in a price between $3.00-$3.14 after having opened the day at $3.01 as compared to the previous trading day's close of $3.00.

Cellectar Biosciences has a market cap of $23.6 million and is part of the health care sector. Shares are down 2.9% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Skystar Bio-Pharmaceutical ( SKBI) was another company that pushed the Drugs industry higher today. Skystar Bio-Pharmaceutical was up $0.05 (3.6%) to $1.43 on light volume. Throughout the day, 13,664 shares of Skystar Bio-Pharmaceutical exchanged hands as compared to its average daily volume of 20,900 shares. The stock ranged in a price between $1.38-$1.43 after having opened the day at $1.38 as compared to the previous trading day's close of $1.38.

Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People's Republic of China. Skystar Bio-Pharmaceutical has a market cap of $12.4 million and is part of the health care sector. Shares are down 67.3% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Skystar Bio-Pharmaceutical a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Skystar Bio-Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from TheStreet Ratings analysis on SKBI go as follows:

  • The revenue growth came in higher than the industry average of 6.8%. Since the same quarter one year prior, revenues rose by 14.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • SKBI's debt-to-equity ratio is very low at 0.16 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.20, which illustrates the ability to avoid short-term cash problems.
  • The gross profit margin for SKYSTAR BIO-PHARMACEUTICAL is rather high; currently it is at 50.16%. Regardless of SKBI's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, SKBI's net profit margin of 26.75% significantly outperformed against the industry.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Pharmaceuticals industry and the overall market, SKYSTAR BIO-PHARMACEUTICAL's return on equity is below that of both the industry average and the S&P 500.
  • SKBI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 72.98%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: Skystar Bio-Pharmaceutical Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.